EH3
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. … Read more
Market Cap & Net Worth: EH3 (EH3)
EH3 (F:EH3) has a market capitalization of $277.46 Million (€270.30 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #13936 globally and #1450 in its home market, demonstrating a 9.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EH3's stock price €13.00 by its total outstanding shares 20792684 (20.79 Million).
EH3 Market Cap History: 2026 to 2026
EH3's market capitalization history from 2026 to 2026. Data shows growth from $277.46 Million to $277.46 Million (0.00% CAGR).
EH3 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EH3's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EH3 by Market Capitalization
Companies near EH3 in the global market cap rankings as of March 18, 2026.
Key companies related to EH3 by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
EH3 Historical Marketcap From 2026 to 2026
Between 2026 and today, EH3's market cap moved from $277.46 Million to $ 277.46 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €277.46 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of EH3 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $277.46 Million USD |
| MoneyControl | $277.46 Million USD |
| MarketWatch | $277.46 Million USD |
| marketcap.company | $277.46 Million USD |
| Reuters | $277.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.